Microcurrent Therapy and the Post-Exercise Physiological Response (MENS_PE) (MENS_PE)

November 9, 2026 updated by: University of Castilla-La Mancha

Microcurrent Therapy and the Post-Exercise Physiological Response: Effects on Creatine Kinase and Associations With Lactate.

The goal of this clinical trial is to find out whether microcurrent therapy changes blood levels of creatine kinase, a marker of muscle stress, during the first 48 hours after exercise in military personnel.

The main question is: Do creatine kinase levels after exercise differ between people who receive active microcurrent therapy and those who receive a sham treatment?

Twenty participants will complete a standardized exercise session. Participants will be randomly assigned to one of two groups: 10 will use an active microcurrent device, and 10 will use a sham device for the same period after exercise. The sham device looks and lights up like the active device but delivers no microcurrents.

Researchers will measure creatine kinase before exercise and 24 and 48 hours afterward, then compare how levels change in the two groups. Investigators will also measure blood lactate and perceived effort shortly after exercise, before either device is applied. Participants will report any difficulties using the device, discomfort, effects on sleep or rest, and unwanted effects.

Study Overview

Detailed Description

Background and study design

Demanding physical exercise can cause physiological changes that persist after the activity has ended. Creatine kinase (CK) is an enzyme whose concentration in the blood can increase following muscle stress. This study will investigate whether prolonged transcutaneous microcurrent therapy after exercise changes the pattern of serum CK concentrations during the first 48 hours of recovery. The study will also characterize the immediate response to exercise and assess the practical use and tolerability of the intervention.

This is a randomized, controlled, parallel-group clinical trial involving 20 participants. Participants will be randomized in a 1:1 ratio to active microcurrent therapy or sham microcurrent therapy, with 10 participants in each group. All participants will complete the same standardized exercise protocol, and both groups will follow the same device application procedure. Participants will apply the devices to both legs for at least seven hours per day on each leg throughout the post-exercise treatment period.

The sham device has been modified so that its indicator light turns on in the same way as the active device, while it delivers no microcurrent output. Participants and outcome assessors will be blinded to group assignment. The personnel responsible for assessing outcomes will not be involved in assigning participants to groups.

Study objectives

Primary objective: To determine the effect of microcurrent therapy on the post-exercise serum creatine kinase response during the first 48 hours of recovery.

Secondary objectives:

Objective 1: To assess the feasibility and tolerability of microcurrent therapy, including difficulties with administration, adverse events, negative effects on sleep or rest.

Objective 2: To characterize the blood lactate response to the standardized exercise protocol and its short-term recovery during the first 30 minutes following exercise.

Objective 3: To characterize the change in perceived exertion immediately after exercise and during the first 30 minutes of recovery.

Objective 4: To assess the success of participant and assessor blinding.

Exploratory objectives:

Exploratory objective 1: To investigate the association between blood lactate concentrations after exercise and CK concentrations at 24 hours and 48 hours

Exploratory objective 2: To examine the relationship between post-exercise lactate concentration and subsequent CK concentration according to treatment allocation.

Exploratory objective 3: To investigate the association between early lactate recovery and early Rating of Perceived Exertion (RPE) recovery.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Toledo
      • Toledo, Toledo, Spain, 45071
        • Campus de Toledo de la Universidad de Castilla-La Mancha (UCLM)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Age between 18 and 45 years.
  • Active-duty military personnel.
  • Healthy volunteers with current medical clearance.
  • Skin over the quadriceps free of lesions, burns, or irritation.
  • Availability and willingness to comply with the proposed intervention protocol.
  • Informed consent form read and signed.

Exclusion Criteria:

  • Implanted electronic devices: pacemakers, defibrillators, neurostimulators, etc.
  • Neuromuscular disease or peripheral neuropathy.
  • Treatment for HIV or chronic viral infections.
  • Uncontrolled seizure disorders (active epilepsy).
  • Uncontrolled, clinically significant heart disease.
  • Depression.
  • Uncontrolled hypertension.
  • Thrombosis.
  • Diabetes with neuropathy or impaired wound healing.
  • Active neoplasms or suspected cancer.
  • Recent musculoskeletal injuries (within the past three months) or chronic muscle pain in a lower limb.
  • Recent major surgery.
  • A dermatological condition in the quadriceps region.
  • Prescription of medications that may confound pain assessment during the seven days before or during the intervention, including nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and systemic corticosteroids.
  • Long-term treatment for hypercholesterolemia.
  • Prescription of antipsychotic or neuroleptic medications.
  • Long-term treatment for hypertriglyceridemia.
  • Alcohol or other substance abuse.
  • Inability to follow the intervention instructions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Active Microcurrent Therapy

Participants randomized to the active microcurrent group will complete the standardized exercise protocol and the immediate and 30-minute post-exercise assessments before beginning treatment. Participants will then apply active transcutaneous microcurrent devices to both legs. Each leg will receive at least seven hours of device application per day throughout the post-exercise treatment period. The devices will deliver microcurrent output while in use. The study team will record any difficulties with application, adverse events, effects on sleep or rest, and perceived unpleasantness.

Prolonged post-exercise transcutaneous microcurrent therapy using an active microcurrent patch applied for minium 7 hours following exercise to promote recovery from exercise-induced muscle fatigue.

Sham Comparator: Sham Microcurrent Therapy

Participants randomized to the sham microcurrent group will complete the standardized exercise protocol and the immediate and 30-minute post-exercise assessments before beginning treatment. The participants will then apply sham devices to both legs. Each leg will receive at least seven hours of device application per day throughout the post-exercise treatment period.

The sham device is the same model as the active device, but it has been modified by an engineer. Its indicator light illuminates in the same way as the active device, while the microcurrent-generating function remains inactive and no microcurrent is delivered. The devices will otherwise be applied in exactly the same way in both groups, preserving participant and outcome-assessor blinding.

The study team will record any difficulties with application, adverse events, effects on sleep or rest, and perceived unpleasantness.

Prolonged post-exercise sham transcutaneous microcurrent intervention using a modified device engineered to reproduce the appearance and operating indicators of the active device, including illumination of the indicator light, while delivering no microcurrent output. The sham device is applied following the same procedure and for the same duration as the active intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum creatine kinase (CK) concentration.
Time Frame: Baseline, 24 hours, and 48 hours after exercise.

Unit: U/L.

Definition: Serum CK concentration will be measured at baseline and during the post- exercise recovery period at 24 and 48 hours. Baseline CK will be calculated as the mean of two measurements obtained one day before and on the day of the exercise protocol.

The primary analysis will evaluate whether the CK concentrations over time differs between the active microcurrent and sham groups.

Baseline, 24 hours, and 48 hours after exercise.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant-perceived feasibility of microcurrent treatment administration
Time Frame: Immediately after the microcurrent treatment period.

Participants will report whether the intervention was easy to administer using a dichotomous response (Yes/No). The outcome will be summarized as the number and percentage of participants answering "Yes".

Immediately after the microcurrent treatment period.
Blood lactate concentration
Time Frame: Pre-exercise, immediately post-exercise, and 30 minutes post-exercise.

Unit: mmol/L.

Definition: blood lactate concentration will be measured at baseline and inmediately post- exercise and at 30 min post-exercise.

The analysis will focus on changes over time during the first 30 minutes of recovery. The primary comparisons will concern the effect of time rather than the effect of treatment group, because all lactate measurements are obtained before microcurrent treatment. These measurements will be considered indicators of biochemical response to the exercise bout rather than measures of the effect of microcurrent therapy.

Pre-exercise, immediately post-exercise, and 30 minutes post-exercise.
Change in perceived exertion after exercise
Time Frame: Immediately post-exercise and 30 minutes post-exercise.

Unit of Measure: Scale points from 0 to 10 Points

Description: Rating of perceived exertion will be assessed using the Borg Category-Ratio 10 Scale immediately after the standardized exercise protocol and 30 minutes later. The recorded score ranges from a minimum of 0 ("nothing at all") to a maximum of 10 ("extremely strong-maximal exertion"). Higher scores indicate greater perceived exertion, representing a less favorable outcome in terms of perceived exertion.

The change in perceived exertion will be calculated as the score at 30 minutes post-exercise minus the score immediately post-exercise. Possible change scores range from -10 to +10. Negative values indicate a reduction in perceived exertion, representing more favorable perceptual recovery; positive values indicate an increase, representing less favorable perceptual recovery.

Immediately post-exercise and 30 minutes post-exercise.
Participant and assessor blinding success
Time Frame: Immediately after completion of the study intervention.

Unit: Categorical responses

Blinding success will be assessed by asking participants and outcome assessors to identify treatment allocation using five predefined response options: (1) strongly believe the treatment was active; (2) somewhat believe the treatment was active; (3) strongly believe the treatment was sham; (4) somewhat believe the treatment was sham; and (5) do not know

Immediately after completion of the study intervention.
Occurrence of adverse events
Time Frame: Immediately after the microcurrent treatment period.

The occurrence of adverse events will be recorded as a yes/no response for each participant. The outcome will be reported as the number of participants experiencing at least one adverse event. The nature and characteristics of reported adverse events will also be documented descriptively.

Immediately after the microcurrent treatment period.
Negative effects on sleep or rest
Time Frame: During and Immediately after the microcurrent treatment period.

Negative effects on sleep or rest during the microcurrent intervention will be assessed using participant-reported yes/no responses. The outcome will be reported as the number of participants reporting at least one negative effect on sleep or rest. The nature of reported effects will also be documented descriptively.

During and Immediately after the microcurrent treatment period.
Perceived unpleasantness of the microcurrent intervention
Time Frame: Immediately after the microcurrent treatment period.

Unit of Measure: Numerical Rating Scale (NRS) score (1-10).

Description: Perceived unpleasantness of the microcurrent intervention will be assessed using a 11-point Numerical Rating Scale (NRS), ranging from 0 ("not unpleasant at all") to 10 ("extremely unpleasant"). Higher scores indicate greater perceived unpleasantness

Immediately after the microcurrent treatment period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Juan Avendaño-Coy, PhD, University of Castilla-La Mancha

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2026

Primary Completion (Actual)

November 1, 2026

Study Completion (Actual)

November 10, 2026

Study Registration Dates

First Submitted

September 30, 2026

First Submitted That Met QC Criteria

October 9, 2026

First Posted (Actual)

October 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

It is planned to make the anonymized datasets publicly available through the Zenodo repository.

IPD Sharing Time Frame

At the time of manuscript submission for publication, after completion of the study

IPD Sharing Access Criteria

The anonymized dataset will be openly accessible to the entire research community through the Zenodo repository, without the need for prior request or approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe